• Publications
  • Influence
A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma.
CONTEXT Pheochromocytomas and paragangliomas (PHEO/PGL) are neuroendocrine tumors that arise from sympathetic and parasympathetic paraganglia. Diagnosed rarely during childhood, PHEO/PGL areExpand
  • 177
  • 17
Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
CONTEXT Pheochromocytomas and sympathetic paragangliomas are rare neuroendocrine tumors for which no precise histological or molecular markers have been identified to differentiate benign fromExpand
  • 242
  • 10
  • PDF
Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center.
OBJECTIVE Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. Herein, we describe the clinical features and outcomes for a large series of ACC patients. DESIGN AND METHODSExpand
  • 133
  • 8
  • PDF
Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma
Pheochromocytomas (PHs) and sympathetic paragangliomas (SPGs) are rare neuroendocrine tumors. Approximately 17 % of these tumors are malignant, but because no molecular or histologic markers forExpand
  • 112
  • 7
Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
CONTEXT Patients with progressive metastatic pheochromocytomas (PHEOs) or sympathetic paragangliomas (SPGLs) face a dismal prognosis. Current systemic therapies are limited. OBJECTIVES The primaryExpand
  • 136
  • 6
Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma.
CONTEXT Bone metastases (BM) can cause severe pain, spinal cord compression, pathological fractures, and/or hypercalcemia. These skeletal-related events (SREs) may cause immobilization, loss ofExpand
  • 61
  • 5
Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra‐adrenal paragangliomas
The objective of this study was to evaluate the clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic paragangliomas by assessing reductions inExpand
  • 90
  • 4
A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma.
CONTEXT Adrenocortical carcinoma (ACC) is a rare malignancy with high recurrence and mortality rates. The role of adjuvant radiation therapy (RT) to improve outcome remains unclear. OBJECTIVE TheExpand
  • 59
  • 4
The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2.
CONTEXT Pheochromocytoma (PHEO) occurs in 50% of patients with multiple endocrine neoplasia type 2 (MEN2). It is unknown if the presence of PHEO is associated with more aggressive medullary thyroidExpand
  • 61
  • 3
Metastatic pheochromocytoma and paraganglioma: focus on therapeutics.
Metastatic pheochromocytomas and paragangliomas are rare and challenging tumors. The tumor burden, combined with excessive catecholamine production, predispose to a broad spectrum of complicationsExpand
  • 85
  • 2